4.6 Article

The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas

期刊

CELL DEATH DISCOVERY
卷 4, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41420-018-0059-0

关键词

-

资金

  1. Ministry of Health, Labour and Welfare (MHLW) for the third-term Comprehensive 10-year Strategy for Cancer Control, Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development, AMED [15ck0106008h0002, 16ck0106008h0003]
  2. National Cancer Center Research and Development Fund [23-B-27[23-A-37], 29-E-6, 23-A-7]

向作者/读者索取更多资源

Anaplastic lymphoma kinase (ALK) is an oncogenic receptor tyrosine kinase that is activated by gene amplification and mutation in neuroblastomas. ALK inhibitors can delay the progression of ALK-driven cancers, but are of limited use owing to ALK inhibitor resistance. Here, we show that resistance to ALK inhibitor in ALK-driven neuroblastomas can be attenuated by combination treatment with a p53 activator. Either ALK inhibition or p53 activator treatment induced cell cycle arrest, whereas combination treatment induced apoptosis, and prevented tumour relapse both in vitro and in vivo. This shift toward apoptosis, and away from cell-cycle arrest, in the presence of an ALK inhibitor and a p53 activator, is mediated by inhibition of the ALK-AKT-FOXO3a axis leading to a specific upregulation of SOX4. SOX4 cooperates with p53 to upregulate the pro-apoptotic protein PUMA. These data therefore suggest a novel combination therapy strategy for treating ALK-driven neuroblastomas.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据